美女免费一级视频在线观看

    1. <form id=BiMYPaeIF><nobr id=BiMYPaeIF></nobr></form>
      <address id=BiMYPaeIF><nobr id=BiMYPaeIF><nobr id=BiMYPaeIF></nobr></nobr></address>

      Skyrizi was the top Rx and over-the-counter (OTC) pharma brand advertising on TV in 2024, according to data released by iSpot.tv on Thursday afternoon.

      AbbVie’s psoriasis, ulcerative colitis, Crohn’s disease and psoriatic arthritis drug had an impressions share of voice (SOV) of 4.14% throughout the year, with 27.3 billion impressions in total.

      The brand received most of its impressions from NBC and benefited from the continued reach of NFL broadcasts.

      Skyrizi had an estimated national TV ad spend of $367.7 million — the highest ad spend of any brand in the top 10. 

      During 2024, Skyrizi was named the top Rx and OTC for TV advertising in Q2 and Q3 as well as the months of July and August. 

      Even in months where it was overtaken by Procter and Gamble’s Vicks, Sanofi and Regeneron’s Dupixent or fellow AbbVie brand Rinvoq, it was consistently near the top of the rankings.

      Finishing in second place for the full year was Dupixent, which recorded an impressions SOV of 4.07% and 26.8 billion impressions.

      The eczema and asthma treatment was also the top brand in both April and May. It spent an estimated $276 million on national TV advertising, enjoying its greatest success on ABC thanks to its flagship evening news program, ABC World News Tonight With David Muir.

      In the third spot was Rinvoq, which had an impressions SOV of 3.38% and 22.3 billion impressions on $337.8 million in estimated spending. The ulcerative colitis, arthritis and eczema treatment topped the rankings in March and received most of its impressions from NBC.

      Rounding out the top five were Vicks and Otsuka’s Rexulti, with 21.5 billion impressions and 15.6 billion impressions, respectively.

      Vicks started off the year strong, claiming the pharma ad crown in January and February before rising to the top again from October through December as cold and flu season gets underway.

      The bottom half of the rankings included Reckitt’s Mucinex, Johnson & Johnson’s Tremfya, Novo Nordisk’s Wegovy, Haleon’s Advil and AstraZeneca’s Breztri Aerosphere. Advil had the lowest estimated national TV ad spend at $45 million.

      Looking at the trends that dominated 2024, iSpot noted that news programming delivered the widest overall reach for the pharma industry.

      Evening news broadcasts from ABC and NBC remain reliable impression generators, though both saw slight year-over-year decreases in impressions 

      Additionally, ABC’s Good Morning America — which ranked fourth for impressions SOV — grew the industry’s reach by 2.5% year-over-year. 

      Though Fox News’ Hannity experienced a 98% year-over-year increase in impressions, it ranked lower than other news programming for industry reach.

      Outside of news programming, pharma benefited from live sports, too.

      MLB broadcasts led the way with a 77% increase in impressions year-over-year, followed by college football at 47%, the NBA at 43%, college basketball at 33% and the NFL at 20%. 

      The data indicated that although primetime programming provided 2.7% more reach than daytime programming, it came at over twice the cost for pharma brands.

      The top daytime offerings included The Price Is Right, The Young and the Restless, Let’s Make a Deal and The View.

      For bargain hunting media buyers, a few cable networks delivered wide reach at lower price tags. These included MSNBC, ION, CNN, TV Land and Oxygen.